Full Press Release Details
Fresenius Medical Care AG resolves share buyback
program with a total volume of EUR 1 billion in tranches within 2 years
Bad Homburg, June 17, 2025 - Fresenius
Medical Care AG ("Company") has decided to conduct a share buyback program with a volume of EUR 1 billion (excluding ancillary
costs) in tranches within two years after the start of the program.
The execution of the share buyback program in
tranches is planned to commence in the second half of 2025. The shares shall be acquired on the stock exchange and are to be predominantly
redeemed and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans.
The share buyback program is based on the authorization
to purchase and use treasury shares granted by the Company's Annual General Meeting on May 20, 2021. Continuation of the share
buyback program beyond the current authorization is subject to the necessary resolutions of the Company's bodies.
Dr. Dominik K. Heger
Head of Investor Relations, Strategic Development & Communications
Executive Vice President